09.08.2012 • News

Eli Lilly Raises 2012 Net Profit Forecast

Eli Lilly on Thursday raised its net profit forecast for 2012 to reflect income from the early payment of financial obligations from former partner Amylin Pharmaceuticals, which has been acquired by Bristol-Myers Squibb.

It said it now expects net earnings per share to range between $3.72 and $3.82. Its forecast for earnings excluding one-time items remains unchanged.

 

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Top-Feature

most read

Photo
News • Chemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.